Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
PanGenomic Health's Sloan Ratio for the quarter that ended in Sep. 2024 was 0.00%.
Warning Sign:
When sloan ratio (-1974.65)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Sep. 2024, PanGenomic Health has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
PanGenomic Health Sloan Ratio % Historical Data
The historical data trend for PanGenomic Health's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PanGenomic Health's Sloan Ratio %
For the Health Information Services subindustry, PanGenomic Health's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PanGenomic Health's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PanGenomic Health's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where PanGenomic Health's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
PanGenomic Health's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
PanGenomic Health's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -0.553 (Dec. 2023 ) + -0.219 (Mar. 2024 ) + -2.542 (Jun. 2024 ) + -0.198 (Sep. 2024 ) = C$-3.51 Mil.
PanGenomic Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was -0.341 (Dec. 2023 ) + 0.016 (Mar. 2024 ) + -0.06 (Jun. 2024 ) + 0.015 (Sep. 2024 ) = C$-0.37 Mil.
PanGenomic Health's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was 0 (Dec. 2023 ) + 0 (Mar. 2024 ) + 0 (Jun. 2024 ) + 0 (Sep. 2024 ) = C$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PanGenomic Health (XCNQ:NARA) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2024, PanGenomic Health has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
PanGenomic Health Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of PanGenomic Health's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
PanGenomic Health Inc is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The company's mobile app, the Nara App, provides consumers with a knowledge base tailored to an individual's user profile, developed by tracking a user's treatment regimen and their specific genomic, proteomics, and microbiome data. The Company's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XCNQ:NARA has been successfully added to your 